Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)

Diseases and Conditions Researched

Alzheimer's Disease

What is the purpose of this trial?

To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

Participation Guidelines

Age: 55 Years - 90 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Eli Lilly and Company
Last Updated:
Study HIC#: 1306012209